Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.
Similar Posts
Consultation on Medical Devices Regulations: Routes to market and in vitro diagnostic devices
The MHRA is inviting members of the public to provide their views on proposed changes to the regulatory framework for medical devices.
First major overhaul of medical device regulation comes into force across Great Britain
New Post-Market Surveillance (PMS) regulations have taken effect across Great Britain, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
MHRA issues new guidance for people using mental health apps and technologies
New online resources will help the public, parents, carers and health, social care and education professionals understand what safe, effective digital mental health technologies look like in practice.
Guidance: AI Airlock Phase 2 application
The call for application for phase 2 of the AI Airlock is now open. This page contains information on eligibility and how to apply
Field Safety Notices: 02-06 February 2026
List of Field Safety Notices: 02-06 February 2026
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26
MHRA transactions over £500 made using the government procurement card (GPC).